Biomarker of Lung Disease in African Americans

非裔美国人肺部疾病的生物标志物

基本信息

批准号：
9980976
负责人：
RUSSELL Paul BOWLER
金额：
$ 79.31万
依托单位：
NATIONAL JEWISH HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-15 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9980976
关键词：
Address Admixture Advanced Glycosylation End Products African African American Asians Biological Markers Blood Cause of Death Chronic Obstructive Airway Disease Clinical Clinical Trials Collaborations Data Diagnostic tests Disease Disease Pathway Disease Progression Distal Early treatment European FDA approved Fibrinogen Functional Imaging Funding Gene Proteins Genetic Genomics Goals Knowledge Latino Lead Longitudinal cohort Lung Lung diseases Messenger RNA MicroRNAs Minority Molecular Molecular Profiling National Heart, Lung, and Blood Institute Not Hispanic or Latino Participant Pathogenesis Pathway interactions Patients Phenotype Plasma Population Population Attributable Risks Precision Health Prevention Proteins Proteomics Publications Pulmonary Emphysema Research Personnel Respiratory physiology Risk Risk Factors Severities Severity of illness Smoker Smoking Testing United States United States National Institutes of Health Whole Blood airway obstruction base biobank chronic airflow obstruction cohort cost disease phenotype disorder risk genetic variant genome sequencing health disparity high risk improved molecular subtypes novel novel diagnostics novel marker outcome forecast precision medicine progression marker protein expression protein protein interaction proteomic signature racial difference receptor smoking-related lung disease transcriptome sequencing transcriptomics treatment strategy virtual whole genome

项目摘要

PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the US1,2. Although COPD occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develops chronic airflow limitation or destruction of distal airspaces (emphysema). Identification molecular profiles from current or former smokers who are likely to progress is a crucial step in understanding the pathogenesis of COPD and emphysema. There are very few publications that describe COPD biomarkers in large, well phenotyped cohorts that include a significant number of African Americans. This study will leverage large NIH- supported cohorts (COPDGene, SPIROMICS, and MESA-Lung) that have large number of well-characterized African Americans subjects with or at risk for COPD. Since the subjects have stored plasma and have been followed for 7-10 years with extensive clinical, physiologic, and imaging, we can very cost-effectively apply a proteomic approach. Furthermore, because the cohorts have other valuable Omics data, we can integrate the proteomic findings with whole genome sequencing and other advanced molecular studies such as genomics. This knowledge may help develop novel diagnostic tests and therapies for early prevention and treatment of COPD and will identify any markers that are specific to smoking-related lung disease in African Americans.

项目摘要/摘要慢性阻塞性肺疾病（COPD）是1,2 US的第三大死亡原因。虽然 COPD主要发生在吸烟者中，尚不清楚为什么只有少数吸烟者（〜20-40％）出现远端空域（肺气肿）的慢性气流限制或破坏。识别分子曲线可能进步的当前或以前的吸烟者是理解的发病机理的关键步骤 COPD和肺气肿。很少有出版物描述COPD生物标志物表型队列包括大量非洲裔美国人。这项研究将利用大型NIH- 具有大量特征的支持队列（Copdgene，螺旋胶和甲虫）非裔美国人受到COPD风险或有风险的受试者。由于受试者存储了血浆，并且已经紧随其后的是7 - 10年，具有广泛的临床，生理和成像，我们可以非常成本地应用蛋白质组学方法。此外，由于队列还具有其他有价值的OMIC数据，因此我们可以集成具有整个基因组测序和其他晚期分子研究（例如基因组学）的蛋白质组学发现。这些知识可能有助于开发新颖的诊断测试和疗法，以提早预防和治疗 COPD并将确定非裔美国人中针对吸烟相关的肺部疾病的任何标记。